Editorial by JHVEPhoto/iStock via Getty Images
- Merck (NYSE:MRK).
- Vibostolimab is an anti-TIGIT antibody, while favezelimab is an anti-LAG-3 antibody.
- The fixed-dose combination of Vibostolimab and Keytruda was
Source link
Merck discontinues development of two antibody programs
Source link